Valuation: FibroBiologics, Inc.

Market Cap 6.47M 5.79M 5.33M 4.83M 9.03M 614M 9.2M 63.56M 25.51M 323M 24.28M 23.76M 1.02B P/E 2026 *
-0.31x
P/E 2027 * -0.53x
Enterprise Value 6.47M 5.79M 5.33M 4.83M 9.03M 614M 9.2M 63.56M 25.51M 323M 24.28M 23.76M 1.02B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.26%
Yield 2026 *
-
Yield 2027 * -
15/10 Fibrobiologics, Inc. Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs CI
08/10 FibroBiologics, Inc. announced that it has received $1.02 million in funding from Peak One Investments, LLC CI
07/10 FibroBiologics, Inc. Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside The Body CI
07/10 FibroBiologics, Inc. announced that it expects to receive $1.02 million in funding from Peak One Investments, LLC CI
23/09 RedChip Companies, Inc., FibroBiologics, Inc. - Special Call
15/09 FibroBiologics, Inc. announced that it has received $0.500001 million in funding CI
27/08 FibroBiologics, Inc. Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial CI
24/08 Fibrobiologics, Inc. Announces Appointment of Leigh Steinberg to Board of Directors CI
20/08 FibroBiologics, Inc. Announces Acceptance of Australian Patent Application for Cannabidiol Adjuvant Therapy for Treatment of Degenerative Disc Disease CI
18/08 FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints CI
01/08 FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
09/07 FibroBiologics, Inc. Announces Appointment of Kathleen 'Kate' Rubins to Board of Directors CI
09/07 FibroBiologics, Inc. Announces the Resignation of Matt Link from the Board of Directors, Effective July 2, 2026 CI
1 day+0.20%
1 week-2.11%
Current month-28.46%
1 month-28.46%
3 months+29.31%
6 months-29.55%
Current year-79.32%
1 week 0.89
Extreme 0.89
0.99
1 month 0.88
Extreme 0.8812
1.24
Current year 0.62
Extreme 0.62005
9.6
1 year 0.62
Extreme 0.62005
9.6
3 years 0.62
Extreme 0.62005
1,100
5 years 0.62
Extreme 0.62005
1,100
10 years 0.62
Extreme 0.62005
1,100
Manager TitleAgeSince
Chief Executive Officer 62 08/04/2021
Director of Finance/CFO 53 09/06/2025
Chief Tech/Sci/R&D Officer 57 01/08/2021
Director TitleAgeSince
Director/Board Member 60 08/04/2021
Chairman 62 08/04/2021
Director/Board Member 67 08/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/9/26 Free

Chief Technology Officer

597,016 8.9666%
8/7/26 Other

Director

562 0.0108%
4/5/26 Free

Chief Executive Officer

92,410 2.6306%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-2.11%-88.28% - 6.46M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
+0.89%+20.55%-42.03%+373.03% 24.37B
Average +0.33%+6.06%+34.25%+206.32% 39.35B
Weighted average by Cap. +0.16%+4.83%+48.30%+185.47%

Financials

2026 *2027 *
Net sales - -
Net income -18.51M -16.58M -15.25M -13.82M -25.82M -1.76B -26.31M -182M -72.99M -924M -69.46M -67.98M -2.92B -22.96M -20.56M -18.91M -17.14M -32.03M -2.18B -32.63M -226M -90.54M -1.15B -86.16M -84.33M -3.62B
Net Debt - -
Projected Income Statement - Annual - FibroBiologics, Inc.
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).
Employees
-
Date Price Change Volume
30/10/26 USD 0.9300 +0.20% 20,671
29/10/26 USD 0.9281 -3.99% 18,066
28/10/26 USD 0.9667 +3.76% 32,378
27/10/26 USD 0.9317 -0.87% 28,788
26/10/26 USD 0.9399 -1.06% 156,670
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - FibroBiologics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9300USD
Average target price
12.50USD
Spread / Average Target
+1,244.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - FibroBiologics, Inc.
  1. Stock Market
  2. Stocks
  3. FBLG Stock